Amneal Pharmaceuticals stock
AMRXNASDAQAmneal Pharmaceuticals, Inc., HealthcareISIN US03168L1052
57Score 57 out of 100, Neutral
Price and trend
88 / 100
Price history
+82% in one yearThe chart shows daily closes over 18 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 35% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is at its 52-week high. Largest decline in 18 years: 98% (April 2015 to March 2023).
Chart figures for advanced users
- SMA 50$19.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.52
- The lowest closing price of the last twelve months.
- Resistance$21.71
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Amneal Pharmaceuticals, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $7.56B, is number 34 of 78 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $3.2B (up 5.9%) and adjusted earnings per share of $1.04 (up 24.3%).
- MEQIRI Score 57 out of 100 (Neutral): rank 316 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $25.40, with the price 15% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 16% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 7%.Profitability 66
Weaknesses
- DilutionShare count up 110% since 2020.Capital allocation 47
- High debtDebt 5.12 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 38
- Interest barely coveredOperating profit covers interest only 1.6 times.Stability 38
Its standout strengths are momentum and technical analysis, while stability and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price up very strongly over the past year
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $19.54 and expensive above $36.28 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $21.10, at 7.8% it would be $31.85.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.9% on the twelve months before. Revenue has grown strongly since 2014, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 38%, operating 14%, net 2%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 26 Feb 2027in 106 days
- Last reported
- 3 Nov 2026EPS reported $0.26 (expected $0.24)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 3.4% since 15 Oct 2026.
- Earnings per share
- $1.04+2.0%
- Revenue
- $3.2B+1.4%
- Earnings per share
- $1.23+3.4%
- Revenue
- $3.49B+1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −4.1%2026 guidance raised: revenue up $50 million to $3.1 billion to $3.2 billion, adjusted EBITDA up $10 million to $750 million to $780 million, EPS to $0.96 to $1.06.
“Also, we're raising our adjusted EBITDA guidance by $10 million between $750 million and $780 million, reflecting strong revenues and higher gross margin. This guidance includes an estimated $20 million of negative impact anticipated as a result of the recent flood in our India facility, as Chintu mentioned earlier on.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $7.22M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Kiely JohnSale
13 Aug 2026, Board
- Shares
- 50,000
- Price
- $17.64
- Value
- $882,000
- Shah NikitaSale
12 Aug 2026, Executive Vice President
- Shares
- 146,403
- Price
- $17.51
- Value
- $2.56M
- Daly Jason B.Sale
12 Aug 2026, EVP, Chief Legal Officer
- Shares
- 210,000
- Price
- $17.40
- Value
- $3.65M
Show 1 more
- Daly Jason B.Sale
11 Aug 2026, EVP, Chief Legal Officer
- Shares
- 6,613
- Price
- $17.70
- Value
- $117,050
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Amneal Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Eisai4523.T $8.91B61
- Krka, d. d.KRK.WA $8.17B74
- Glenmark PharmaceuticalsGLENMARK.NS $8.06B74
- AlkermesALKS $8.05B53
- Huadong Medicine000963.SZ $6.98B62
- Alkem LaboratoriesALKEM.NS $6.95B65
- Lantheus HoldingsLNTH $6.64B76
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
ETFs that hold Amneal Pharmaceuticals
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.45% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.21% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.14% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.11% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.11% | 0.30% | €4.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.04% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.